360 related articles for article (PubMed ID: 21447398)
1. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice.
Li J; Semple K; Suh WK; Liu C; Chen F; Blazar BR; Yu XZ
Biol Blood Marrow Transplant; 2011 Jul; 17(7):962-9. PubMed ID: 21447398
[TBL] [Abstract][Full Text] [Related]
2. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
[TBL] [Abstract][Full Text] [Related]
3. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Vallera DA
Blood; 1995 May; 85(9):2607-18. PubMed ID: 7537122
[TBL] [Abstract][Full Text] [Related]
4. CD28-specific antibody prevents graft-versus-host disease in mice.
Yu XZ; Bidwell SJ; Martin PJ; Anasetti C
J Immunol; 2000 May; 164(9):4564-8. PubMed ID: 10779758
[TBL] [Abstract][Full Text] [Related]
5. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
[TBL] [Abstract][Full Text] [Related]
6. CTLA4-Ig-Based Bifunctional Costimulation Inhibitor Blocks CD28 and ICOS Signaling to Prevent T Cell Priming and Effector Function.
Goenka R; Xu Z; Samayoa J; Banach D; Beam C; Bose S; Dooner G; Forsyth CM; Lu X; Medina L; Sadhukhan R; Sielaff B; Sousa S; Tao Q; Touw D; Wu F; Kingsbury GA; Akamatsu Y
J Immunol; 2021 Mar; 206(5):1102-1113. PubMed ID: 33495237
[TBL] [Abstract][Full Text] [Related]
7. Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation.
Gonzalo JA; Delaney T; Corcoran J; Goodearl A; Gutierrez-Ramos JC; Coyle AJ
J Immunol; 2001 Jan; 166(1):1-5. PubMed ID: 11123268
[TBL] [Abstract][Full Text] [Related]
8. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
[TBL] [Abstract][Full Text] [Related]
9. Targeting T cell costimulation in autoimmune disease.
Stuart RW; Racke MK
Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.
Lin H; Rathmell JC; Gray GS; Thompson CB; Leiden JM; Alegre ML
J Exp Med; 1998 Jul; 188(1):199-204. PubMed ID: 9653096
[TBL] [Abstract][Full Text] [Related]
11. Acute graft-versus-host disease without costimulation via CD28.
Speiser DE; Bachmann MF; Shahinian A; Mak TW; Ohashi PS
Transplantation; 1997 Apr; 63(7):1042-4. PubMed ID: 9112366
[TBL] [Abstract][Full Text] [Related]
12. JTA-009, a fully human antibody against human AILIM/ICOS, ameliorates graft-vs-host reaction in SCID mice grafted with human PBMCs.
Tajima N; Tezuka K; Tanimoto A; Miyai A; Tanimoto M; Maruhashi J; Watanabe Y
Exp Hematol; 2008 Nov; 36(11):1514-23. PubMed ID: 18715691
[TBL] [Abstract][Full Text] [Related]
13. Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.
Sato M; Storb R; Loretz C; Stone D; Mielcarek M; Sale GE; Rezvani AR; Graves SS
Transplantation; 2013 Jul; 96(1):34-41. PubMed ID: 23694952
[TBL] [Abstract][Full Text] [Related]
14. The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis.
Wiendl H; Neuhaus O; Mehling M; Wintterle S; Schreiner B; Mitsdoerffer M; Wienhold W; Weissert R; Wessels J; Hartung HP; Weller M; Tolosa E; Melms A
J Neuroimmunol; 2003 Jul; 140(1-2):177-87. PubMed ID: 12864987
[TBL] [Abstract][Full Text] [Related]
15. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice.
Blazar BR; Taylor PA; Linsley PS; Vallera DA
Blood; 1994 Jun; 83(12):3815-25. PubMed ID: 7515723
[TBL] [Abstract][Full Text] [Related]
16. Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells.
Yu XZ; Liang Y; Nurieva RI; Guo F; Anasetti C; Dong C
J Immunol; 2006 Jun; 176(12):7394-401. PubMed ID: 16751384
[TBL] [Abstract][Full Text] [Related]
17. Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL.
Zuberek K; Ling V; Wu P; Ma HL; Leonard JP; Collins M; Dunussi-Joannopoulos K
Cell Immunol; 2003 Sep; 225(1):53-63. PubMed ID: 14643304
[TBL] [Abstract][Full Text] [Related]
18. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28.
Saito K; Sakurai J; Ohata J; Kohsaka T; Hashimoto H; Okumura K; Abe R; Azuma M
J Immunol; 1998 May; 160(9):4225-31. PubMed ID: 9574523
[TBL] [Abstract][Full Text] [Related]
19. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
[TBL] [Abstract][Full Text] [Related]
20. A role for inducible costimulator protein in the CD28- independent mechanism of resistance to Toxoplasma gondii.
Villegas EN; Lieberman LA; Mason N; Blass SL; Zediak VP; Peach R; Horan T; Yoshinaga S; Hunter CA
J Immunol; 2002 Jul; 169(2):937-43. PubMed ID: 12097399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
